Selected Start-Ups (6/01)
Executive SummaryIn Vivo summarizes the technologies of several recently founded companies: Archemix Corp. will use its proprietary nucleic acid engineering technology to build protein detection chips and multiplexed assays for use in drug discovery. Gel-Del Technologies Inc. is developing protein-based biomaterials for making implanted medical devices more acceptable to the human body. Neuro Therapeutics Inc. was spun out of the University of British Columbia to commercialize therapies for stimulating repair of injured neurons after traumatic injury of the spinal cord or brain. OncoGenex Technologies Inc. aims to develop and commercialize therapeutics for hormone-independent prostate cancer. Rejuvenon Corp. aims to turn back the hands of time with drugs to treat or prevent disorders related to aging. A new entrant in the cardiovascular diagnostics arena, Belgium's Thermocore Medical Systems NV is developing a thermographic catheter-based system to localize and visualize unstable coronary plaque.
You may also be interested in...
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.